Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03886311 · ClinicalTrials.gov registry record · Phase 2
Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma
A Phase 2 study of Sarcoma, sponsored by Sarcoma Oncology Research Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT03886311 is a Phase 2 study of Sarcoma that is actively recruiting participants, run by Sarcoma Oncology Research Center. The registered enrollment target is 200 participants, below the 920-participant average among 122 other Sarcoma trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03886311, a Phase 2 study of Sarcoma, is actively recruiting participants, sponsored by Sarcoma Oncology Research Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin as first, second or third line therapy for advanced sarcoma, including desmoid tumor and chordoma.
Conditions Studied
Interventions
- DRUG Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC]
- DRUG Nivolumab IV Soln 100 MG/10ML
- DRUG Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution
Study Locations (1)
California
- Sarcoma Oncology Center - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2019-05-15 |
| Est. Completion | 2031-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03886311
The ClinicalTrials.gov registry entry for NCT03886311 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 920-participant average among 122 other Sarcoma trials with a reported enrollment target (78% lower). The listed sponsor is Sarcoma Oncology Research Center, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 3 interventions - of which Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC] is the first listed.
NCT03886311 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03886311 about?
NCT03886311 is a clinical study titled "Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma". This is a Phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin as first, second or third line therapy for advanced sarcoma, including desmoid tumor and chordoma.
What is the current status of trial NCT03886311?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2019-05-15. Estimated completion is 2031-07-31.
What conditions does trial NCT03886311 study?
This clinical trial studies the following conditions: Sarcoma.
What interventions are being tested in trial NCT03886311?
The interventions under investigation include: Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC] (DRUG), Nivolumab IV Soln 100 MG/10ML (DRUG), Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution (DRUG).
Who is sponsoring clinical trial NCT03886311?
This trial is sponsored by Sarcoma Oncology Research Center, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03886311 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
RECRUITING · Phase 2
-
Fluorescent Intra-operative Tumor Margin Examination
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.